A detailed history of Aqr Capital Management LLC transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Aqr Capital Management LLC holds 33,718 shares of ABUS stock, worth $108,234. This represents 0.0% of its overall portfolio holdings.

Number of Shares
33,718
Holding current value
$108,234
% of portfolio
0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.12 - $4.56 $105,200 - $153,754
33,718 New
33,718 $129,000
Q3 2023

Nov 14, 2023

BUY
$1.9 - $2.27 $49,542 - $59,190
26,075 Added 179.54%
40,598 $82,000
Q2 2023

Aug 14, 2023

SELL
$2.24 - $3.06 $14,362 - $19,620
-6,412 Reduced 30.63%
14,523 $33,000
Q1 2023

May 15, 2023

SELL
$2.23 - $3.1 $4,054 - $5,635
-1,818 Reduced 7.99%
20,935 $63,000
Q4 2022

Feb 14, 2023

SELL
$1.91 - $2.85 $131 - $196
-69 Reduced 0.3%
22,753 $53,000
Q3 2022

Nov 14, 2022

BUY
$1.88 - $2.88 $6,376 - $9,768
3,392 Added 17.46%
22,822 $44,000
Q2 2022

Aug 15, 2022

BUY
$1.98 - $3.17 $38,471 - $61,593
19,430 New
19,430 $53,000
Q3 2021

Nov 15, 2021

SELL
$2.65 - $4.62 $50,445 - $87,946
-19,036 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$2.5 - $3.51 $47,590 - $66,816
19,036 New
19,036 $58,000
Q2 2019

Aug 14, 2019

SELL
$1.46 - $4.44 $41,066 - $124,888
-28,128 Closed
0 $0
Q1 2019

May 14, 2019

SELL
$3.41 - $4.57 $318,882 - $427,358
-93,514 Reduced 76.88%
28,128 $101,000
Q4 2018

Feb 14, 2019

BUY
$3.5 - $9.66 $262,731 - $725,137
75,066 Added 161.17%
121,642 $466,000
Q3 2018

Nov 15, 2018

BUY
$7.85 - $12.35 $214,728 - $337,821
27,354 Added 142.31%
46,576 $440,000
Q2 2018

Aug 14, 2018

BUY
$5.0 - $7.35 $96,110 - $141,281
19,222 New
19,222 $140,000

Others Institutions Holding ABUS

About Arbutus Biopharma Corp


  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $481M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track Aqr Capital Management LLC Portfolio

Follow Aqr Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aqr Capital Management LLC with notifications on news.